The P38 MAPK Signaling Activation in Colorectal Cancer Upon Therapeutic Treatments

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Apr 23

PMID 32316313

Citations 23

Authors

Angelina Pranteda

Valentina Piastra

Lorenzo Stramucci

Deborah Fratantonio

Gianluca Bossi

Affiliations

Soon will be listed here.

Abstract

Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents. In the case of rectal carcinoma, radiation therapy also represents a therapeutic strategy. In an attempt at translating much-needed new targeted therapy to the clinics, p38 mitogen activated protein kinase (MAPK) inhibitors have been tested in clinical trials involving colorectal carcinoma patients, especially in combination with chemotherapy; however, despite the high expectations raised by a clear involvement of the p38 MAPK pathway in the response to therapeutic treatments, poor results have been obtained so far. In this work, we review recent insights into the exact role of the p38 MAPK pathway in response to currently available therapies for colorectal carcinoma, depicting an intricate scenario in which the p38 MAPK node presents many opportunities, as well as many challenges, for its perspective exploitation for clinical purposes.

Citing Articles

MAPK Signaling-Mediated RFNG Phosphorylation and Nuclear Translocation Restrain Oxaliplatin-Induced Apoptosis and Ferroptosis.

Di Y, Zhang X, Wen X, Qin J, Ye L, Wang Y Adv Sci (Weinh). 2024; 11(38):e2402795.

PMID: 39120977 PMC: 11481204. DOI: 10.1002/advs.202402795.

Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis.

Rosenberger G, Li W, Turunen M, He J, Subramaniam P, Pampou S Nat Commun. 2024; 15(1):3909.

PMID: 38724493 PMC: 11082183. DOI: 10.1038/s41467-024-47957-3.

Targeting the Cdc2-like kinase 2 for overcoming platinum resistance in ovarian cancer.

Jiang Y, Huang S, Zhang L, Zhou Y, Zhang W, Wan T MedComm (2020). 2024; 5(4):e537.

PMID: 38617434 PMC: 11016135. DOI: 10.1002/mco2.537.

The Essential Oil from (L.) Cronquist (Asteraceae) Exerts an In Vitro Antimelanoma Effect by Inducing Apoptosis and Modulating the MAPKs, NF-κB, and PKB/AKT Signaling Pathways.

Ferreira R, Sousa Duarte S, Sousa V, de Souza R, Marques K, de Abrantes R Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004419 PMC: 10674350. DOI: 10.3390/ph16111553.

MicroRNA-144-3p protects against chemotherapy-induced apoptosis of ovarian granulosa cells and activation of primordial follicles by targeting MAP3K9.

Liu M, Xiao B, Zhu Y, Chen M, Huang J, Guo H Eur J Med Res. 2023; 28(1):264.

PMID: 37537658 PMC: 10399062. DOI: 10.1186/s40001-023-01231-2.

References

Berger M, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y . Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. Ann Oncol. 2017; 28(11):2780-2785. PMC: 5834083. DOI: 10.1093/annonc/mdx412. View

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A . Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients. Br J Cancer. 2010; 102(7):1137-44. PMC: 2853100. DOI: 10.1038/sj.bjc.6605612. View

Liu J, Huang W, Lee K, Tung S, Chen C, Chang S . Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells. J Cell Biochem. 2018; 119(10):8472-8480. DOI: 10.1002/jcb.27073. View

Koizumi K, Tanno S, Nakano Y, Habiro A, Izawa T, Mizukami Y . Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res. 2005; 25(5):3347-53. View

Chung H, Choi H, Seo E, Kang D, Oh E . Baicalin and baicalein inhibit transforming growth factor-β1-mediated epithelial-mesenchymal transition in human breast epithelial cells. Biochem Biophys Res Commun. 2015; 458(3):707-713. DOI: 10.1016/j.bbrc.2015.02.032. View

Garcia-Cano J, Roche O, Cimas F, Pascual-Serra R, Ortega-Muelas M, Fernandez-Aroca D . p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story. Front Cell Dev Biol. 2016; 4:69. PMC: 4928511. DOI: 10.3389/fcell.2016.00069. View

Pommier Y, Leo E, Zhang H, Marchand C . DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010; 17(5):421-33. PMC: 7316379. DOI: 10.1016/j.chembiol.2010.04.012. View

de la Cruz-Morcillo M, Valero M, Callejas-Valera J, Arias-Gonzalez L, Melgar-Rojas P, Galan-Moya E . P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. Oncogene. 2011; 31(9):1073-85. DOI: 10.1038/onc.2011.321. View

Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-Capetillo O, Nebreda A . p38 Mitogen-activated protein kinase- and HuR-dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S checkpoint. Mol Cell Biol. 2009; 29(16):4341-51. PMC: 2725730. DOI: 10.1128/MCB.00210-09. View

10.

Rakitina T, Vasilevskaya I, ODwyer P . Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling. Cancer Res. 2003; 63(24):8600-5. View

11.

Alcindor T, Beauger N . Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1):18-25. PMC: 3031353. DOI: 10.3747/co.v18i1.708. View

12.

Jiang Y, Wu C, Boye A, Wu J, Wang J, Yang X . MAPK inhibitors modulate Smad2/3/4 complex cyto-nuclear translocation in myofibroblasts via Imp7/8 mediation. Mol Cell Biochem. 2015; 406(1-2):255-62. DOI: 10.1007/s11010-015-2443-x. View

13.

Keshet Y, Seger R . The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol. 2010; 661:3-38. DOI: 10.1007/978-1-60761-795-2_1. View

14.

Chen M, Lee N, Hsu H, Ho T, Tu C, Hsieh D . Thymoquinone induces caspase-independent, autophagic cell death in CPT-11-resistant lovo colon cancer via mitochondrial dysfunction and activation of JNK and p38. J Agric Food Chem. 2015; 63(5):1540-6. DOI: 10.1021/jf5054063. View

15.

Fazeli M, Keramati M . Rectal cancer: a review. Med J Islam Repub Iran. 2015; 29:171. PMC: 4431429. View

16.

Hou J, Lam F, Proud C, Wang S . Targeting Mnks for cancer therapy. Oncotarget. 2012; 3(2):118-31. PMC: 3326643. DOI: 10.18632/oncotarget.453. View

17.

Sanchez-Arevalo Lobo V, Aceves Luquero C, Alvarez-Vallina L, Tipping A, Viniegra J, Hernandez Losa J . Modulation of the p38 MAPK (mitogen-activated protein kinase) pathway through Bcr/Abl: implications in the cellular response to Ara-C. Biochem J. 2004; 387(Pt 1):231-8. PMC: 1134951. DOI: 10.1042/BJ20040927. View

18.

Saltz L . Irinotecan in the first-line treatment of colorectal cancer. Oncology (Williston Park). 1998; 12(8 Suppl 6):54-8. View

19.

Galan-Moya E, Hernandez-Losa J, Aceves Luquero C, de la Cruz-Morcillo M, Ramirez-Castillejo C, Callejas-Valera J . c-Abl activates p38 MAPK independently of its tyrosine kinase activity: Implications in cisplatin-based therapy. Int J Cancer. 2007; 122(2):289-97. DOI: 10.1002/ijc.23063. View

20.

Chocry M, Leloup L, Kovacic H . Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway. Oncotarget. 2017; 8(61):103710-103730. PMC: 5732761. DOI: 10.18632/oncotarget.21780. View